Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: tom r. phillips who wrote (804)	4/15/2004 10:33:58 AM
From: Icebrg	Read Replies (2) \| Respond to of 2240

I don't think one should read too much into that. At least not until Genmab has an approved product. The Copenhagen stock exchange has a very limited exposure to biotech companies, why it is reasonable to suppose that retail investors (who drive the price short-term) are not particularly well-informed about a the risks facing a company like Genmab. The share price has risen as more drugs have been pushed further into the pipeline, but it will crash badly if the company encounters problems. Something biotech companies invariably does. Erik